Could a diabetes injection help early Parkinson's patients?

NCT ID NCT03439943

Completed Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 trial tested whether lixisenatide, a daily injection already used for diabetes, could slow the worsening of motor symptoms in 156 people with early Parkinson's disease. Participants received either the drug or a placebo for 12 months, alongside their usual Parkinson's medications. The study measured changes in movement disability to see if lixisenatide has a disease-modifying effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lixisenatide (a daily injection used for diabetes, repurposed for Parkinson's)
What this could lead to: If successful, this could point toward a treatment that slows the worsening of movement problems in early Parkinson's disease.
What could go wrong: This is a small, early-stage (Phase 2) proof-of-concept trial, so results may not confirm benefit. The drug can cause nausea and other side effects, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

CHU Toulouse

Toulouse, 31000, France
Creteil- Henri Mondor Hospital

Créteil, France
Pitié Salpêtrière Hospital

Paris, France
University Hospital of Amiens

Amiens, France
University Hospital of Besancon

Besançon, France
University Hospital of Bordeaux

Bordeaux, France
University Hospital of Caen

Caen, France
University Hospital of Clermont-Ferrand

Clermont-Ferrand, France
University Hospital of Lille

Lille, France
University Hospital of Limoges

Limoges, France
University Hospital of Lyon

Lyon, France
University Hospital of Marseille

Marseille, France
University Hospital of Montpellier

Montpellier, France
University Hospital of Nancy

Nancy, France
University Hospital of Nantes

Nantes, France
University Hospital of Nice

Nice, France
University Hospital of Poitiers

Poitiers, France
University Hospital of Rennes

Rennes, France
University Hospital of Rouen

Rouen, France
University Hospital of Strasbourg

Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.